Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2097946794', 'doi': 'https://doi.org/10.1158/0008-5472.can-05-0259', 'title': '<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants', 'display_name': '<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants', 'publication_year': 2005, 'publication_date': '2005-06-01', 'ids': {'openalex': 'https://openalex.org/W2097946794', 'doi': 'https://doi.org/10.1158/0008-5472.can-05-0259', 'mag': '2097946794', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/15930265'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/0008-5472.can-05-0259', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'green', 'oa_url': 'https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_i_In_vitro_i_Activity_of_Bcr-Abl_Inhibitors_AMN107_and_BMS-354825_against_Clinically_Relevant_Imatinib-Resistant_Abl_Kinase_Domain_Mutants/22363796/1/files/39808019.pdf', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5029672494', 'display_name': 'Thomas O’Hare', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1344073410', 'display_name': 'Howard Hughes Medical Institute', 'ror': 'https://ror.org/006w34k90', 'country_code': 'US', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I1344073410']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': "Thomas O'Hare", 'raw_affiliation_strings': ['1Howard Hughes Medical Institute and'], 'affiliations': [{'raw_affiliation_string': '1Howard Hughes Medical Institute and', 'institution_ids': ['https://openalex.org/I1344073410']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5014701529', 'display_name': 'Denise K. Walters', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1344073410', 'display_name': 'Howard Hughes Medical Institute', 'ror': 'https://ror.org/006w34k90', 'country_code': 'US', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I1344073410']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Denise K. Walters', 'raw_affiliation_strings': ['1Howard Hughes Medical Institute and'], 'affiliations': [{'raw_affiliation_string': '1Howard Hughes Medical Institute and', 'institution_ids': ['https://openalex.org/I1344073410']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5018193219', 'display_name': 'Eric P. Stoffregen', 'orcid': 'https://orcid.org/0000-0003-0550-004X'}, 'institutions': [{'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Eric P. Stoffregen', 'raw_affiliation_strings': ['2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;'], 'affiliations': [{'raw_affiliation_string': '2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;', 'institution_ids': ['https://openalex.org/I165690674']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5055703306', 'display_name': 'Taiping Jia', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Taiping Jia', 'raw_affiliation_strings': ['2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;'], 'affiliations': [{'raw_affiliation_string': '2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;', 'institution_ids': ['https://openalex.org/I165690674']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5013829081', 'display_name': 'Paul W. Manley', 'orcid': 'https://orcid.org/0000-0002-9722-7863'}, 'institutions': [{'id': 'https://openalex.org/I1283582996', 'display_name': 'Novartis (Switzerland)', 'ror': 'https://ror.org/02f9zrr09', 'country_code': 'CH', 'type': 'company', 'lineage': ['https://openalex.org/I1283582996']}], 'countries': ['CH'], 'is_corresponding': False, 'raw_author_name': 'Paul W. Manley', 'raw_affiliation_strings': ['4Novartis Institutes for Biomedical Research, Basel, Switzerland; and'], 'affiliations': [{'raw_affiliation_string': '4Novartis Institutes for Biomedical Research, Basel, Switzerland; and', 'institution_ids': ['https://openalex.org/I1283582996']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5077097430', 'display_name': 'Jürgen Mestan', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1283582996', 'display_name': 'Novartis (Switzerland)', 'ror': 'https://ror.org/02f9zrr09', 'country_code': 'CH', 'type': 'company', 'lineage': ['https://openalex.org/I1283582996']}], 'countries': ['CH'], 'is_corresponding': False, 'raw_author_name': 'Jürgen Mestan', 'raw_affiliation_strings': ['4Novartis Institutes for Biomedical Research, Basel, Switzerland; and'], 'affiliations': [{'raw_affiliation_string': '4Novartis Institutes for Biomedical Research, Basel, Switzerland; and', 'institution_ids': ['https://openalex.org/I1283582996']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5054649453', 'display_name': 'Sandra W. Cowan‐Jacob', 'orcid': 'https://orcid.org/0000-0003-1657-2719'}, 'institutions': [{'id': 'https://openalex.org/I1283582996', 'display_name': 'Novartis (Switzerland)', 'ror': 'https://ror.org/02f9zrr09', 'country_code': 'CH', 'type': 'company', 'lineage': ['https://openalex.org/I1283582996']}], 'countries': ['CH'], 'is_corresponding': False, 'raw_author_name': 'Sandra W. Cowan-Jacob', 'raw_affiliation_strings': ['4Novartis Institutes for Biomedical Research, Basel, Switzerland; and'], 'affiliations': [{'raw_affiliation_string': '4Novartis Institutes for Biomedical Research, Basel, Switzerland; and', 'institution_ids': ['https://openalex.org/I1283582996']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5086704967', 'display_name': 'Francis Y. Lee', 'orcid': 'https://orcid.org/0000-0003-2275-2441'}, 'institutions': [{'id': 'https://openalex.org/I4210091812', 'display_name': 'Bristol-Myers Squibb (United States)', 'ror': 'https://ror.org/00gtmwv55', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210091812']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Francis Y. Lee', 'raw_affiliation_strings': ['5Bristol-Myers Squibb Oncology, Princeton, New Jersey'], 'affiliations': [{'raw_affiliation_string': '5Bristol-Myers Squibb Oncology, Princeton, New Jersey', 'institution_ids': ['https://openalex.org/I4210091812']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5091057405', 'display_name': 'Michael C. Heinrich', 'orcid': 'https://orcid.org/0000-0003-3790-0478'}, 'institutions': [{'id': 'https://openalex.org/I2803065977', 'display_name': 'Portland VA Medical Center', 'ror': 'https://ror.org/02v3txv81', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1322918889', 'https://openalex.org/I2799886695', 'https://openalex.org/I2803065977', 'https://openalex.org/I4210144745']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Michael C. Heinrich', 'raw_affiliation_strings': ['3Portland Veterans Affairs Medical Center, Portland, Oregon;'], 'affiliations': [{'raw_affiliation_string': '3Portland Veterans Affairs Medical Center, Portland, Oregon;', 'institution_ids': ['https://openalex.org/I2803065977']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5007755609', 'display_name': 'Michael W. Deininger', 'orcid': 'https://orcid.org/0000-0002-2987-1331'}, 'institutions': [{'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Michael W.N. Deininger', 'raw_affiliation_strings': ['2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;'], 'affiliations': [{'raw_affiliation_string': '2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;', 'institution_ids': ['https://openalex.org/I165690674']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5033023115', 'display_name': 'Brian J. Druker', 'orcid': 'https://orcid.org/0000-0001-8331-8206'}, 'institutions': [{'id': 'https://openalex.org/I1344073410', 'display_name': 'Howard Hughes Medical Institute', 'ror': 'https://ror.org/006w34k90', 'country_code': 'US', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I1344073410']}, {'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Brian J. Druker', 'raw_affiliation_strings': ['1Howard Hughes Medical Institute and', '2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;'], 'affiliations': [{'raw_affiliation_string': '1Howard Hughes Medical Institute and', 'institution_ids': ['https://openalex.org/I1344073410']}, {'raw_affiliation_string': '2Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute;', 'institution_ids': ['https://openalex.org/I165690674']}]}], 'countries_distinct_count': 2, 'institutions_distinct_count': 5, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 41.435, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 1028, 'citation_normalized_percentile': {'value': 0.999809, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 99, 'max': 100}, 'biblio': {'volume': '65', 'issue': '11', 'first_page': '4500', 'last_page': '4505'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11215', 'display_name': 'Efficacy and Resistance in CML Treatment', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11215', 'display_name': 'Efficacy and Resistance in CML Treatment', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12600', 'display_name': 'Hypereosinophilic Syndrome and Related Disorders', 'score': 0.9973, 'subfield': {'id': 'https://openalex.org/subfields/2745', 'display_name': 'Rheumatology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11157', 'display_name': 'Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia', 'score': 0.9945, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/chronic-myelogenous-leukemia', 'display_name': 'Chronic myelogenous leukemia', 'score': 0.64585793}, {'id': 'https://openalex.org/keywords/abl', 'display_name': 'ABL', 'score': 0.62145543}, {'id': 'https://openalex.org/keywords/protein-kinase-domain', 'display_name': 'Protein kinase domain', 'score': 0.5462321}, {'id': 'https://openalex.org/keywords/imatinib', 'display_name': 'Imatinib', 'score': 0.527399}, {'id': 'https://openalex.org/keywords/imatinib-mesylate', 'display_name': 'Imatinib mesylate', 'score': 0.52644855}, {'id': 'https://openalex.org/keywords/btk-inhibitors', 'display_name': 'BTK Inhibitors', 'score': 0.512005}, {'id': 'https://openalex.org/keywords/tyrosine-kinase-inhibitors', 'display_name': 'Tyrosine Kinase Inhibitors', 'score': 0.503279}], 'concepts': [{'id': 'https://openalex.org/C2777583451', 'wikidata': 'https://www.wikidata.org/wiki/Q177094', 'display_name': 'Imatinib', 'level': 3, 'score': 0.9252964}, {'id': 'https://openalex.org/C42362537', 'wikidata': 'https://www.wikidata.org/wiki/Q87099740', 'display_name': 'Tyrosine kinase', 'level': 3, 'score': 0.6501257}, {'id': 'https://openalex.org/C2776960273', 'wikidata': 'https://www.wikidata.org/wiki/Q729735', 'display_name': 'Chronic myelogenous leukemia', 'level': 3, 'score': 0.64585793}, {'id': 'https://openalex.org/C2777413986', 'wikidata': 'https://www.wikidata.org/wiki/Q412327', 'display_name': 'Nilotinib', 'level': 4, 'score': 0.6248586}, {'id': 'https://openalex.org/C125418893', 'wikidata': 'https://www.wikidata.org/wiki/Q587961', 'display_name': 'ABL', 'level': 4, 'score': 0.62145543}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.5956692}, {'id': 'https://openalex.org/C2778820342', 'wikidata': 'https://www.wikidata.org/wiki/Q906415', 'display_name': 'Tyrosine-kinase inhibitor', 'level': 3, 'score': 0.54900926}, {'id': 'https://openalex.org/C32619005', 'wikidata': 'https://www.wikidata.org/wiki/Q24768234', 'display_name': 'Protein kinase domain', 'level': 4, 'score': 0.5462321}, {'id': 'https://openalex.org/C3019892230', 'wikidata': 'https://www.wikidata.org/wiki/Q177094', 'display_name': 'Imatinib mesylate', 'level': 4, 'score': 0.52644855}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.50944716}, {'id': 'https://openalex.org/C2779536868', 'wikidata': 'https://www.wikidata.org/wiki/Q419940', 'display_name': 'Dasatinib', 'level': 4, 'score': 0.4393623}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.39435744}, {'id': 'https://openalex.org/C185592680', 'wikidata': 'https://www.wikidata.org/wiki/Q2329', 'display_name': 'Chemistry', 'level': 0, 'score': 0.32721025}, {'id': 'https://openalex.org/C2778461978', 'wikidata': 'https://www.wikidata.org/wiki/Q29496', 'display_name': 'Leukemia', 'level': 2, 'score': 0.31502557}, {'id': 'https://openalex.org/C143065580', 'wikidata': 'https://www.wikidata.org/wiki/Q3285695', 'display_name': 'Mutant', 'level': 3, 'score': 0.26873243}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.22994971}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.10088304}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.07183537}, {'id': 'https://openalex.org/C55493867', 'wikidata': 'https://www.wikidata.org/wiki/Q7094', 'display_name': 'Biochemistry', 'level': 1, 'score': 0.05591601}, {'id': 'https://openalex.org/C2778729363', 'wikidata': 'https://www.wikidata.org/wiki/Q11688946', 'display_name': 'Myeloid leukemia', 'level': 2, 'score': 0.0}, {'id': 'https://openalex.org/C104317684', 'wikidata': 'https://www.wikidata.org/wiki/Q7187', 'display_name': 'Gene', 'level': 2, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D010879', 'descriptor_name': 'Piperazines', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D011505', 'descriptor_name': 'Protein-Tyrosine Kinases', 'qualifier_ui': 'Q000037', 'qualifier_name': 'antagonists & inhibitors', 'is_major_topic': True}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D000818', 'descriptor_name': 'Animals', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D001549', 'descriptor_name': 'Benzamides', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002460', 'descriptor_name': 'Cell Line', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000069439', 'descriptor_name': 'Dasatinib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016044', 'descriptor_name': 'Fusion Proteins, bcr-abl', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000068877', 'descriptor_name': 'Imatinib Mesylate', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': False}, {'descriptor_ui': 'D015464', 'descriptor_name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'qualifier_ui': 'Q000201', 'qualifier_name': 'enzymology', 'is_major_topic': False}, {'descriptor_ui': 'D051379', 'descriptor_name': 'Mice', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008958', 'descriptor_name': 'Models, Molecular', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D010879', 'descriptor_name': 'Piperazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D047428', 'descriptor_name': 'Protein Kinase Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017434', 'descriptor_name': 'Protein Structure, Tertiary', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011505', 'descriptor_name': 'Protein-Tyrosine Kinases', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011505', 'descriptor_name': 'Protein-Tyrosine Kinases', 'qualifier_ui': 'Q000235', 'qualifier_name': 'genetics', 'is_major_topic': False}, {'descriptor_ui': 'D011743', 'descriptor_name': 'Pyrimidines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013844', 'descriptor_name': 'Thiazoles', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 4, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/0008-5472.can-05-0259', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1158/0008-5472.22363796', 'pdf_url': 'https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_i_In_vitro_i_Activity_of_Bcr-Abl_Inhibitors_AMN107_and_BMS-354825_against_Clinically_Relevant_Imatinib-Resistant_Abl_Kinase_Domain_Mutants/22363796/1/files/39808019.pdf', 'source': None, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'submittedVersion', 'is_accepted': False, 'is_published': False}, {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1158/0008-5472.22363793', 'pdf_url': 'https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_2_from_i_In_vitro_i_Activity_of_Bcr-Abl_Inhibitors_AMN107_and_BMS-354825_against_Clinically_Relevant_Imatinib-Resistant_Abl_Kinase_Domain_Mutants/22363793/1/files/39808016.pdf', 'source': None, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'submittedVersion', 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/15930265', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1158/0008-5472.22363796', 'pdf_url': 'https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_i_In_vitro_i_Activity_of_Bcr-Abl_Inhibitors_AMN107_and_BMS-354825_against_Clinically_Relevant_Imatinib-Resistant_Abl_Kinase_Domain_Mutants/22363796/1/files/39808019.pdf', 'source': None, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'submittedVersion', 'is_accepted': False, 'is_published': False}, 'sustainable_development_goals': [], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 24, 'referenced_works': ['https://openalex.org/W1607745684', 'https://openalex.org/W1973720500', 'https://openalex.org/W1974884195', 'https://openalex.org/W1997577435', 'https://openalex.org/W2026389791', 'https://openalex.org/W2028959752', 'https://openalex.org/W2030154801', 'https://openalex.org/W2048258225', 'https://openalex.org/W2087430484', 'https://openalex.org/W2090004346', 'https://openalex.org/W2092606584', 'https://openalex.org/W2124196948', 'https://openalex.org/W2125135039', 'https://openalex.org/W2131174104', 'https://openalex.org/W2131476854', 'https://openalex.org/W2137601120', 'https://openalex.org/W2148763134', 'https://openalex.org/W2151818038', 'https://openalex.org/W2154169171', 'https://openalex.org/W2171722798', 'https://openalex.org/W2312804644', 'https://openalex.org/W2329648702', 'https://openalex.org/W2526549242', 'https://openalex.org/W2975250779'], 'related_works': ['https://openalex.org/W2890336441', 'https://openalex.org/W2888908066', 'https://openalex.org/W2763572665', 'https://openalex.org/W2558695847', 'https://openalex.org/W2551715108', 'https://openalex.org/W24999251', 'https://openalex.org/W2230151041', 'https://openalex.org/W2155615242', 'https://openalex.org/W2013963600', 'https://openalex.org/W1992121712'], 'abstract_inverted_index': {'Abstract': [0], 'Imatinib,': [1], 'a': [2, 8, 124], 'Bcr-Abl': [3, 53, 63, 84, 154], 'tyrosine': [4], 'kinase': [5, 54, 64, 128], 'inhibitor,': [6], 'is': [7], 'highly': [9, 102], 'effective': [10], 'therapy': [11], 'for': [12, 75, 161, 176], 'patients': [13, 37, 76], 'with': [14, 38, 57, 166], 'chronic': [15, 24], 'myelogenous': [16], 'leukemia': [17], '(CML).': [18], 'Despite': [19], 'durable': [20], 'responses': [21], 'in': [22, 36, 90, 118], 'most': [23, 42], 'phase': [25], 'patients,': [26], 'relapses': [27], 'have': [28, 67], 'been': [29, 50], 'observed': [30], 'and': [31, 100, 116, 120, 140, 144, 155], 'are': [32, 86, 142, 159], 'much': [33], 'more': [34, 146], 'prevalent': [35], 'advanced': [39], 'disease.': [40], 'The': [41], 'common': [43], 'mechanism': [44], 'of': [45, 126, 133, 169], 'acquired': [46], 'imatinib': [47, 59, 80, 149], 'resistance': [48], 'has': [49], 'traced': [51], 'to': [52], 'domain': [55, 129], 'mutations': [56], 'decreased': [58], 'sensitivity.': [60], 'Thus,': [61, 171], 'alternate': [62], 'inhibitors': [65, 85, 173], 'that': [66, 138, 156], 'activity': [68], 'against': [69, 123, 150], 'imatinib-resistant': [70, 163], 'mutants': [71, 130, 164], 'would': [72], 'be': [73], 'useful': [74], 'who': [77], 'relapse': [78], 'on': [79], 'therapy.': [81], 'Two': [82], 'such': [83], 'currently': [87], 'being': [88], 'evaluated': [89], 'clinical': [91, 134], 'trials:': [92], 'the': [93, 101, 109, 167], 'improved': [94], 'potency,': [95], 'selective': [96], 'Abl': [97], 'inhibitor': [98, 106], 'AMN107': [99, 139], 'potent': [103, 147], 'dual': [104], 'Src/Abl': [105], 'BMS-354825.': [107], 'In': [108], 'current': [110], 'article,': [111], 'we': [112], 'compared': [113], 'imatinib,': [114], 'AMN107,': [115], 'BMS-354825': [117, 141], 'cellular': [119], 'biochemical': [121], 'assays': [122], 'panel': [125], '16': [127], 'representing': [131], '&gt;90%': [132], 'isolates.': [135], 'We': [136], 'report': [137], '20-fold': [143], '325-fold': [145], 'than': [148], 'cells': [151], 'expressing': [152], 'wild-type': [153], 'similar': [157], 'improvements': [158], 'maintained': [160], 'all': [162], 'tested,': [165], 'exception': [168], 'T315I.': [170], 'both': [172], 'hold': [174], 'promise': [175], 'treating': [177], 'imatinib-refractory': [178], 'CML.': [179]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2097946794', 'counts_by_year': [{'year': 2024, 'cited_by_count': 12}, {'year': 2023, 'cited_by_count': 19}, {'year': 2022, 'cited_by_count': 33}, {'year': 2021, 'cited_by_count': 31}, {'year': 2020, 'cited_by_count': 29}, {'year': 2019, 'cited_by_count': 30}, {'year': 2018, 'cited_by_count': 32}, {'year': 2017, 'cited_by_count': 32}, {'year': 2016, 'cited_by_count': 39}, {'year': 2015, 'cited_by_count': 34}, {'year': 2014, 'cited_by_count': 37}, {'year': 2013, 'cited_by_count': 72}, {'year': 2012, 'cited_by_count': 65}], 'updated_date': '2024-09-11T01:26:44.217716', 'created_date': '2016-06-24'}